Newer Agents in Antiplatelet Therapy: a Review

Overview

Journal J Blood Med

Publisher Dove Medical Press

Specialty Hematology

Date 2012 Jul 14

PMID 22792011

Citations 23

Authors

Jennifer Yeung

Michael Holinstat

Affiliations

Soon will be listed here.

Abstract

Antiplatelet therapy remains the mainstay in preventing aberrant platelet activation in pathophysiological conditions such as myocardial infarction, ischemia, and stroke. Although there has been significant advancement in antiplatelet therapeutic approaches, aspirin still remains the gold standard treatment in the clinical setting. Limitations in safety, efficacy, and tolerability have precluded many of the antiplatelet inhibitors from use in patients. Unforeseen incidences of increased bleeding risk and recurrent arterial thrombosis observed in patients have hampered the development of superior next generation antiplatelet therapies. The pharmacokinetic and pharmacodynamic profiles have also limited the effectiveness of a number of antiplatelet inhibitors currently in use due to variability in metabolism, time to onset, and reversibility. A focused effort in the development of newer antiplatelet therapies to address some of these shortcomings has resulted in a significant number of potential antiplatelet drugs which target enzymes (phosphodiesterase, cyclooxygenase), receptors (purinergic, prostaglandins, protease-activated receptors, thromboxane), and glycoproteins (αIIbβ3, GPVI, vWF, GPIb) in the platelet. The validation and search for newer antiplatelet therapeutic approaches proven to be superior to aspirin is still ongoing and should yield a better pharmacodynamic profile with fewer untoward side-effects to what is currently in use today.

Citing Articles

Non-coding RNA therapeutics in cardiovascular diseases and risk factors: Systematic review.

Ardiana M, Fadila A, Zuhra Z, Kusuma N, Rurus M, Oceandy D Noncoding RNA Res. 2023; 8(4):487-506.

PMID: 37483458 PMC: 10362275. DOI: 10.1016/j.ncrna.2023.06.002.

Targeting Platelet Activation Pathways to Limit Tumour Progression: Current State of Affairs.

Xulu K, Augustine T Pharmaceuticals (Basel). 2022; 15(12).

PMID: 36558983 PMC: 9784118. DOI: 10.3390/ph15121532.

Comparative Study of Ex Vivo Antiplatelet Activity of Aspirin and Cilostazol in Patients with Diabetes and High Risk of Cardiovascular Disease.

Hong S, Lee W, Park C Endocrinol Metab (Seoul). 2022; 37(2):233-242.

PMID: 35381686 PMC: 9081299. DOI: 10.3803/EnM.2021.1353.

Antiplatelet Activity of Isorhamnetin via Mitochondrial Regulation.

Rodriguez L, Badimon L, Mendez D, Padro T, Vilahur G, Pena E Antioxidants (Basel). 2021; 10(5).

PMID: 33922903 PMC: 8146847. DOI: 10.3390/antiox10050666.

Antiplatelet Activity of Tussilagone via Inhibition of the GPVI Downstream Signaling Pathway in Platelets.

Zhou J, Yang R, Song W, Xu H, Wang Y Front Med (Lausanne). 2020; 7:380.

PMID: 32850895 PMC: 7403204. DOI: 10.3389/fmed.2020.00380.

References

Diener H, Cunha L, Forbes C, Sivenius J, Smets P, LOWENTHAL A . European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci. 1996; 143(1-2):1-13. DOI: 10.1016/s0022-510x(96)00308-5. View

Kleiman N, Lincoff A, Flaker G, Pieper K, Wilcox R, Berdan L . Early percutaneous coronary intervention, platelet inhibition with eptifibatide, and clinical outcomes in patients with acute coronary syndromes. PURSUIT Investigators. Circulation. 2000; 101(7):751-7. DOI: 10.1161/01.cir.101.7.751. View

Liu Y, Fong M, Cone J, Wang S, Yoshitake M, Kambayashi J . Inhibition of adenosine uptake and augmentation of ischemia-induced increase of interstitial adenosine by cilostazol, an agent to treat intermittent claudication. J Cardiovasc Pharmacol. 2000; 36(3):351-60. DOI: 10.1097/00005344-200009000-00011. View

Post J, Alexander S, Wang Y, Vincelette J, Vergona R, Kent L . Novel P2Y12 adenosine diphosphate receptor antagonists for inhibition of platelet aggregation (II): pharmacodynamic and pharmacokinetic characterization. Thromb Res. 2008; 122(4):533-40. DOI: 10.1016/j.thromres.2008.04.009. View

Yusuf S, Zhao F, Mehta S, Chrolavicius S, Tognoni G, Fox K . Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001; 345(7):494-502. DOI: 10.1056/NEJMoa010746. View

Tchana-Sato V, Dogne J, Lambermont B, Ghuysen A, Magis D, Morimont P . Effects of BM-573, a thromboxane A2 modulator on systemic hemodynamics perturbations induced by U-46619 in the pig. Prostaglandins Other Lipid Mediat. 2005; 78(1-4):82-95. DOI: 10.1016/j.prostaglandins.2005.04.001. View

Suh J, Lee S, Park K, Lee H, Kang H, Koo B . Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy.... J Am Coll Cardiol. 2011; 57(3):280-9. DOI: 10.1016/j.jacc.2010.08.631. View

Gent M, Blakely J, Easton J, Ellis D, Hachinski V, Harbison J . The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet. 1989; 1(8649):1215-20. DOI: 10.1016/s0140-6736(89)92327-1. View

Gilbert J, DeFeo-Fraulini T, Hutabarat R, Horvath C, Merlino P, Marsh H . First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers. Circulation. 2007; 116(23):2678-86. DOI: 10.1161/CIRCULATIONAHA.107.724864. View

10.

Kastrati A, Mehilli J, Schuhlen H, Dirschinger J, Dotzer F, Ten Berg J . A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med. 2004; 350(3):232-8. DOI: 10.1056/NEJMoa031859. View

11.

Montalescot G, Wiviott S, Braunwald E, Murphy S, Gibson C, McCabe C . Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet. 2009; 373(9665):723-31. DOI: 10.1016/S0140-6736(09)60441-4. View

12.

Gurbel P, Bliden K, Antonino M, Stephens G, Gretler D, Jurek M . The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP2C19*2 genotype: first experience in patients. J Thromb Haemost. 2009; 8(1):43-53. DOI: 10.1111/j.1538-7836.2009.03648.x. View

13.

Morrow D, Scirica B, Fox K, Berman G, Strony J, Veltri E . Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2.... Am Heart J. 2009; 158(3):335-341.e3. DOI: 10.1016/j.ahj.2009.06.027. View

14.

Harrington R, Stone G, McNulty S, White H, Lincoff A, Gibson C . Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med. 2009; 361(24):2318-29. DOI: 10.1056/NEJMoa0908628. View

15.

Kleiman N, Raizner A, Jordan R, Wang A, Norton D, Mace K . Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GPIIb/IIIa receptors. J Am Coll Cardiol. 1995; 26(7):1665-71. DOI: 10.1016/0735-1097(95)00391-6. View

16.

Scarborough R, Rose J, Hsu M, Phillips D, Fried V, Campbell A . Barbourin. A GPIIb-IIIa-specific integrin antagonist from the venom of Sistrurus m. barbouri. J Biol Chem. 1991; 266(15):9359-62. View

17.

Chackalamannil S, Wang Y, Greenlee W, Hu Z, Xia Y, Ahn H . Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity. J Med Chem. 2008; 51(11):3061-4. DOI: 10.1021/jm800180e. View

18.

Chintala M, Strony J, Yang B, Kurowski S, Li Q . SCH 602539, a protease-activated receptor-1 antagonist, inhibits thrombosis alone and in combination with cangrelor in a Folts model of arterial thrombosis in cynomolgus monkeys. Arterioscler Thromb Vasc Biol. 2010; 30(11):2143-9. DOI: 10.1161/ATVBAHA.110.203414. View

19.

Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Meneveau N . Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2008; 360(4):363-75. DOI: 10.1056/NEJMoa0808227. View

20.

Mahaffey K, Wojdyla D, Carroll K, Becker R, Storey R, Angiolillo D . Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation. 2011; 124(5):544-54. DOI: 10.1161/CIRCULATIONAHA.111.047498. View